BACKGROUND AND PURPOSE: To analyze the efficacy and safety of a new preoperative intensity-modulated radiotherapy (IMRT) and integrated-boost chemoradiation scheme. PATIENTS AND METHODS: In all, 74 patients were treated with IMRT and concurrent standard dose capecitabine. The dose of the planning target volume (PTV) encompassing the tumor, mesorectum, and pelvic lymph nodes was 46 Gy in 23 fractions; the boost PTV, at a dose of 57.5 Gy in 23 fractions, included the macroscopic primary tumor and pathological lymph nodes. The patients underwent surgery 6-8 weeks after chemoradiation. RESULTS: The complete treatment data of 72 patients were analyzed. Tumor downstaging was achieved in 55 patients (76.38 %) and node downstaging in 34 (47.2 %). In 22 patients (30.6 %), there was complete pathological response (ypCR). The circumferential resection margin was free of tumor in 70 patients (97.2 %). The 3-year estimated overall survival and disease-free survival rates were 95.4 and 85.9 % respectively, and no local relapse was found; however, ten patients (13.8 %) developed distant metastases. High pathologic tumor (pT) downstaging was shown as a favorable prognostic factor for disease-free survival. No grade 4 acute radiotherapy-related toxicity was found. CONCLUSIONS: The IMRT and integrated-boost chemoradiation scheme offered higher rates of ypCR and pT downstaging, without a significant increase in toxicity. The circumferential margins were free of tumors in the majority of patients. Primary tumor regression was associated with better disease-free survival.
BACKGROUND AND PURPOSE: To analyze the efficacy and safety of a new preoperative intensity-modulated radiotherapy (IMRT) and integrated-boost chemoradiation scheme. PATIENTS AND METHODS: In all, 74 patients were treated with IMRT and concurrent standard dose capecitabine. The dose of the planning target volume (PTV) encompassing the tumor, mesorectum, and pelvic lymph nodes was 46 Gy in 23 fractions; the boost PTV, at a dose of 57.5 Gy in 23 fractions, included the macroscopic primary tumor and pathological lymph nodes. The patients underwent surgery 6-8 weeks after chemoradiation. RESULTS: The complete treatment data of 72 patients were analyzed. Tumor downstaging was achieved in 55 patients (76.38 %) and node downstaging in 34 (47.2 %). In 22 patients (30.6 %), there was complete pathological response (ypCR). The circumferential resection margin was free of tumor in 70 patients (97.2 %). The 3-year estimated overall survival and disease-free survival rates were 95.4 and 85.9 % respectively, and no local relapse was found; however, ten patients (13.8 %) developed distant metastases. High pathologic tumor (pT) downstaging was shown as a favorable prognostic factor for disease-free survival. No grade 4 acute radiotherapy-related toxicity was found. CONCLUSIONS: The IMRT and integrated-boost chemoradiation scheme offered higher rates of ypCR and pT downstaging, without a significant increase in toxicity. The circumferential margins were free of tumors in the majority of patients. Primary tumor regression was associated with better disease-free survival.
Authors: J-P Machiels; L Duck; B Honhon; B Coster; J-C Coche; P Scalliet; Y Humblet; S Aydin; J Kerger; V Remouchamps; J-L Canon; P Van Maele; L Gilbeau; S Laurent; C Kirkove; M Octave-Prignot; J-F Baurain; A Kartheuser; C Sempoux Journal: Ann Oncol Date: 2005-10-11 Impact factor: 32.976
Authors: J F Bosset; V Magnin; P Maingon; G Mantion; E P Pelissier; M Mercier; G Chaillard; J C Horiot Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: Gary M Freedman; Neal J Meropol; Elin R Sigurdson; John Hoffman; Elaine Callahan; Robert Price; Jonathan Cheng; Steve Cohen; Nancy Lewis; Deborah Watkins-Bruner; André Rogatko; Andre Konski Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-01 Impact factor: 7.038
Authors: Ari Ballonoff; Brian Kavanagh; Martin McCarter; Madeleine Kane; Nathan Pearlman; Russell Nash; Raj J Shah; David Raben; Tracey E Schefter Journal: Am J Clin Oncol Date: 2008-06 Impact factor: 2.339
Authors: Annelies Debucquoy; Sarah Roels; Laurence Goethals; Louis Libbrecht; Eric Van Cutsem; Karel Geboes; Freddy Penninckx; André D'Hoore; William H McBride; Karin Haustermans Journal: Radiother Oncol Date: 2009-09-09 Impact factor: 6.280
Authors: F Alongi; S Fersino; R Mazzola; A Fiorentino; N Giaj-Levra; F Ricchetti; R Ruggieri; G Di Paola; M Cirillo; S Gori; M Salgarello; G Zamboni; G Ruffo Journal: Clin Transl Oncol Date: 2016-06-07 Impact factor: 3.405
Authors: Leif Hendrik Dröge; Hanne Elisabeth Weber; Manuel Guhlich; Martin Leu; Lena-Christin Conradi; Jochen Gaedcke; Steffen Hennies; Markus Karl Herrmann; Margret Rave-Fränk; Hendrik Andreas Wolff Journal: BMC Cancer Date: 2015-10-20 Impact factor: 4.430
Authors: Bong Kyung Bae; Min Kyu Kang; Jae-Chul Kim; Mi Young Kim; Gyu-Seog Choi; Jong Gwang Kim; Byung Woog Kang; Hye Jin Kim; Soo Yeun Park Journal: Radiat Oncol J Date: 2017-09-29